Component
Omeprazole
Omeprazole
3 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What it acts on
In 14 healthy volunteers, omeprazole-induced anacidity slightly reduced release of orally administered labeled liver cobalamins in gastric aspirates at 5 and 30 minutes versus placebo.
Experimental context and source evidence
- cross_nutrient
- false
- experimental_model
- Double-blind crossover in 14 healthy humans using 57Co-labeled rabbit liver
- exposure
- Short-term omeprazole versus placebo; dose not in inspected abstract
- limitations
- Short-term food tracer experiment, not a long-term deficiency outcome.
- nutrient_topic
- Vitamin B12 research collection; topical membership is not evidence of a direct dietary effect. · Vitamin B12 (cobalamins)
- organism
- Homo sapiens
- plain_language
- Suppressing acid delayed early stomach release in this experiment.
- primary_references
- [kittang-1987-anacidity] Effect of gastric anacidity on the release of cobalamins from food and their subsequent binding to R-protein. (1987). https://pubmed.ncbi.nlm.nih.gov/3423731/ DOI: 10.3109/00365528708991952
- tissue_or_cell_type
- Stomach lumen
Vitamin B12: mechanisms, deficiency and nutrient interactions (2026-09-17) · lines 127–138
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Double-blind crossover in 14 healthy humans using 57Co-labeled rabbit liver · source_derived_draft · unverified_draft
### b12-abs-anacidity-gastric In 14 healthy volunteers, omeprazole-induced anacidity slightly reduced release of orally administered labeled liver cobalamins in gastric aspirates at 5 and 30 minutes versus placebo. Condition category: normal nutrient_topic: Vitamin B12 research collection; topical membership is not evidence of a direct dietary effect. plain_language: Suppressing acid delayed early stomach release in this experiment. organism: Homo sapiens tissue_or_cell_type: Stomach lumen experimental_model: Double-blind crossover in 14 healthy humans using 57Co-labeled rabbit liver limitations: Short-term food tracer experiment, not a long-term deficiency outcome. exposure: Short-term omeprazole versus placebo; dose not in inspected abstract cross_nutrient: false [kittang-1987-anacidity] Effect of gastric anacidity on the release of cobalamins from food and their subsequent binding to R-protein. (1987). https://pubmed.ncbi.nlm.nih.gov/3423731/ DOI: 10.3109/00365528708991952
Complete structured claim and evidenceIn the same crossover experiment, jejunal release of labeled liver cobalamins was near 90% after either omeprazole or placebo, despite earlier gastric effects.
Experimental context and source evidence
- cross_nutrient
- false
- experimental_model
- Double-blind crossover in 14 healthy humans using 57Co-labeled rabbit liver
- exposure
- Short-term omeprazole versus placebo
- limitations
- Luminal release is not systemic absorption; this observation cannot exclude long-term effects on status.
- nutrient_topic
- Vitamin B12 research collection; topical membership is not evidence of a direct dietary effect. · Vitamin B12 (cobalamins)
- organism
- Homo sapiens
- plain_language
- Most liver-bound B12 was still released by the jejunum.
- primary_references
- [kittang-1987-anacidity] Effect of gastric anacidity on the release of cobalamins from food and their subsequent binding to R-protein. (1987). https://pubmed.ncbi.nlm.nih.gov/3423731/ DOI: 10.3109/00365528708991952
- tissue_or_cell_type
- Upper jejunal lumen
Vitamin B12: mechanisms, deficiency and nutrient interactions (2026-09-17) · lines 140–151
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Double-blind crossover in 14 healthy humans using 57Co-labeled rabbit liver · source_derived_draft · unverified_draft
### b12-abs-anacidity-jejunum In the same crossover experiment, jejunal release of labeled liver cobalamins was near 90% after either omeprazole or placebo, despite earlier gastric effects. Condition category: normal nutrient_topic: Vitamin B12 research collection; topical membership is not evidence of a direct dietary effect. plain_language: Most liver-bound B12 was still released by the jejunum. organism: Homo sapiens tissue_or_cell_type: Upper jejunal lumen experimental_model: Double-blind crossover in 14 healthy humans using 57Co-labeled rabbit liver limitations: Luminal release is not systemic absorption; this observation cannot exclude long-term effects on status. exposure: Short-term omeprazole versus placebo cross_nutrient: false [kittang-1987-anacidity] Effect of gastric anacidity on the release of cobalamins from food and their subsequent binding to R-protein. (1987). https://pubmed.ncbi.nlm.nih.gov/3423731/ DOI: 10.3109/00365528708991952
Complete structured claim and evidence
Where it participates (unsigned role)
No statistically significant change in omeprazole probe pharmacokinetics was found after berberine.
Experimental context and source evidence
- evidence_span
- {"source_cache": "artifacts/berberine-research/21870106.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "12e465c3c0a8ce995697a6fb9bf77c079e38b413e82c8b4f2a82e45a3dbf8ae5", "start_char": 0, "end_char": 1817, "text_sha256": "12e465c3c0a8ce995697a6fb9bf77c079e38b413e82c8b4f2a82e45a3dbf8ae5"}
- experimental_model
- Two-phase randomized crossover enzyme-phenotyping study
- exposure
- Berberine 300 mg three times daily for 14 days versus placebo
- limitations
- Small short-term study. Probe metabolic ratios are not percentage inhibition of every substrate. No universal dose-adjustment rule; no statistically significant effect is not equivalence.
- nutrient_topic
- Berberine research collection; topical membership is not evidence of a direct dietary effect. · Berberine
- organism
- Healthy human male volunteers; 17 completed
- plain_language
- The CYP2C19 probe result was also negative under these conditions.
- primary_references
- [berberine-p21870106] Repeated administration of berberine inhibits cytochromes P450 in humans. (2012). https://pubmed.ncbi.nlm.nih.gov/21870106/ DOI: 10.1007/s00228-011-1108-2
- tissue_or_cell_type
- Oral probe pharmacokinetics and urinary metabolite ratios
Berberine: metabolism, nutrient connections and drug interactions (2026-09-17) · lines 688–699
AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text. · supports · Two-phase randomized crossover enzyme-phenotyping study · source_derived_draft · unverified_draft
### berberine-human-cyp-2c19-null No statistically significant change in omeprazole probe pharmacokinetics was found after berberine. Condition category: normal nutrient_topic: Berberine research collection; topical membership is not evidence of a direct dietary effect. plain_language: The CYP2C19 probe result was also negative under these conditions. organism: Healthy human male volunteers; 17 completed tissue_or_cell_type: Oral probe pharmacokinetics and urinary metabolite ratios experimental_model: Two-phase randomized crossover enzyme-phenotyping study limitations: Small short-term study. Probe metabolic ratios are not percentage inhibition of every substrate. No universal dose-adjustment rule; no statistically significant effect is not equivalence. exposure: Berberine 300 mg three times daily for 14 days versus placebo evidence_span: {"source_cache": "artifacts/berberine-research/21870106.abstract.txt", "locator": "Primary indexed abstract; zero-based, end-exclusive Unicode character offsets", "file_sha256": "12e465c3c0a8ce995697a6fb9bf77c079e38b413e82c8b4f2a82e45a3dbf8ae5", "start_char": 0, "end_char": 1817, "text_sha256": "12e465c3c0a8ce995697a6fb9bf77c079e38b413e82c8b4f2a82e45a3dbf8ae5"} [berberine-p21870106] Repeated administration of berberine inhibits cytochromes P450 in humans. (2012). https://pubmed.ncbi.nlm.nih.gov/21870106/ DOI: 10.1007/s00228-011-1108-2
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.